Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) EBT (2016 - 2025)

Amphastar Pharmaceuticals (AMPH) has 13 years of EBT data on record, last reported at -$97.0 million in Q4 2025.

  • For Q4 2025, EBT fell 296.53% year-over-year to -$97.0 million; the TTM value through Dec 2025 reached -$5.3 million, down 102.73%, while the annual FY2025 figure was -$5.3 million, 102.73% down from the prior year.
  • EBT reached -$97.0 million in Q4 2025 per AMPH's latest filing, down from $21.5 million in the prior quarter.
  • Across five years, EBT topped out at $63.6 million in Q3 2023 and bottomed at -$97.0 million in Q4 2025.
  • Average EBT over 5 years is $29.2 million, with a median of $33.2 million recorded in 2023.
  • Peak YoY movement for EBT: surged 1045.28% in 2021, then plummeted 296.53% in 2025.
  • A 5-year view of EBT shows it stood at $27.2 million in 2021, then surged by 93.0% to $52.4 million in 2022, then decreased by 0.98% to $51.9 million in 2023, then fell by 4.88% to $49.4 million in 2024, then tumbled by 296.53% to -$97.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$97.0 million in Q4 2025, $21.5 million in Q3 2025, and $39.3 million in Q2 2025.